La reactogenicidad de Nirsevimab aumenta con la administración concomitante de vacunas sistemáticas infantiles
Carcione D, Spencer Ph, Pettigrew G et al. Active post-marketing safety surveillance of Nirsevimab administered to children in Western Australia, April-July 2024. The Pediatric Infectious Disease Journal published on line January 3, 2025 https://journals.lww.com/pidj/fulltext/9900/active_post_marketing_safety_surveillance_of.1156.aspx En abril 2024 el Western Australian (WA) Department of Health comenzó a administrar Nirsevimab a los niños nacidos desde el 1…
